Global Market Study on Flu Vaccines: Preventive over Reactive


Flu Vaccines  Market
  • Published On : Jul-2019 |
  • Pages : 195 Pages |
  • Format :

Flu Vaccine Market – Analysis and Opportunity Assessment

Persistence Market Insights (PMR), in its new publication, outlines the growth trails of ‘Flu Vaccine Market’ for the period between 2019 and 2029. The study includes a thorough analysis of historical and current trends that can impact the future development of flu vaccine market. It offers various drivers, restrains, challenges, and opportunities in the flu vaccine market. The report brings to fore actionable insights on nodes and internodes of the flu vaccine market that can arm the vendors with necessary information to take critical decision with confidence.

PMR’s study covers a key indicator assessment to estimate the growth prospects of the flu vaccine market during the predefined period, along with forecast statistics in terms of value (US$ million). In addition, the report consists of multiple sections explaining the global healthcare spending outlook and awareness about flu and flu vaccination.

Readers can find a detailed taxonomy in the report, along with an incisive outlook on the competitive landscape in flu vaccine market. The study profiles a number of incumbent companies and new entrants in the flu market, wherein, product portfolio, new launches, technological innovations, and dynamic growth strategies of these players have been detailed.

Flu Vaccine Market – Segmentation

Key information featured in the flu vaccine market report has been segmented into four broader categories – type, dosage form, distribution channel, and region. The report includes different dynamics and trends related to individual segments, and assesses their impact on the overall growth of the flu vaccine market. Market value share analysis and market attractiveness assessment of the segments have also been provided in this section of the report.

Product

Dosage Form

Distribution Channel

Region

Trivalent Flu Vaccine

Intramuscular Injection

Institutional Sales

North America

Quadrivalent Flu Vaccine

Nasal Spray

  • Hospitals

Latin America

Intradermal Shot

  • Community Clinics

Europe

  • Public Health Agencies

South Asia

  • Workplace Purchasing

East Asia

Retail Sales

Oceania

  • Retail Pharmacy

Middle East & Africa

  • Mail Order Pharmacy

What are the Key Questions Answered in the Flu Vaccine Market Report?

PMR’s study assesses the flu vaccine market at both macroscopic and microscopic levels to offer detailed insights that can help determine sustained opportunities for the stakeholders. Exclusive information provided in the flu vaccine market report addresses various important questions required to understand and gain comprehensive knowledge about the market. Some of these questions are:

  • How is regulatory framework in different nations affecting the growth of flu vaccine market?
  • How has the flu vaccine market performed so far and how will it perform in the next decade?
  • What are winning strategies of key players in the flu vaccine market?
  • What are the opportunities market stakeholders are eyeing to strengthen their position in the global market?
  • What are development risks and competitive threats faced by the flu vaccine market players across different regions?

Research Methodology

The research methodology followed for obtaining complete information regarding the developments in flu vaccine market involves conducting an in-depth market research with the help of various primary and secondary resources. By analyzing the information gathered through and verified by these resources, analysts could offer exclusive insights on how the flu vaccine market will grow and expand during the predefined period.

Analysts have conducted interviews and discussion with healthcare consultants, CEOs, KOLs, regional officers, and sales managers of companies in the supply chain of flu vaccine drugs. The data obtained through these discussions have contributed to the development of the flu vaccine market report as a primary resource.

Secondary resources referred by the analysts for the compilation of flu vaccine market report include company annual and financial reports, white papers, industrial association publications, research publications, and leading industry magazines. Other secondary resources are Global Alliance of Vaccine and Immunization (Gavi), International Society of Vaccines, and IFPMA.

A paradigm shift in focus--away from traditional systems of healthcare, in which healthcare professionals treat patients after they fall ill--to a novel system supporting well-being, prevention and early intervention is influencing the colossal healthcare industry. However, in the current scenario, many diseases continue to take their toll on human health, despite decades of scientific endeavor. Among these, prevention and mitigation of influenza virus continues to be a longstanding challenge for stakeholders, including healthcare providers and pharma companies.

flu vaccine market strategy

At the height of influenza outbreaks, headlines often claim, ‘novel’ and ‘next-generation’ flu vaccines. However, understanding the nature of outbreaks remains important for healthcare providers as well as patients to make informed decisions regarding influenza prevention. Future Market Insights (FMI), in its new offering, analyzes how research on influenza viruses will influence future prospects of the ‘Flu Vaccine Market’. It also offers a lucid analysis of the market that can help identify lucrative opportunities for stakeholders.

Flu Vaccine Market – The Past, Present, and the Future

Post the discovery of influenza virus in early 1930s, the first flu vaccine was not approved until mid-1940s for both military and civilian use. With new research techniques and manufacturing technologies, newer and more effective vaccines entered the market at a quick pace.

By 2018, the global flu vaccine market value reached approximately US$ 4 billion, and increasing demand, new target population in low- and mid-income countries, and growing awareness of flu vaccination continued to influence the market growth. A notable rise in global healthcare spending along with growing efforts to increase flu vaccination rate to limit the outbreaks of infectious diseases, has also been weighing on same scale as the growth of flu vaccine market.

However, the demand for flu vaccines is largely dependent on severity of seasonal flu across different geographies, and the unpredictable nature of the seasonal flu has led to a supply-demand gap. Additionally, strictly sterile manufacturing procedures of flu vaccines take months and include purification, quality testing, safety controls, and packaging and regulatory verifications – delaying the access to vaccines during an outbreak.

Quadrivalent Vaccines – The Flu Vaccine of Choice

As a large number of awareness campaigns regarding infectious diseases helped boost the rate of vaccination across the globe, many biotech companies are constantly working on novel solutions to significantly improve the protection rates offered by current vaccines. Quadrivalent flu vaccines continue to account for higher demand, with approximately 80% revenue share in 2018, as compared to their trivalent counterparts. Designed to protect against two different lineages of both influenza A and influenza B viruses, FDA-approved quadrivalent flu vaccines are also widely adopted to include newly selected flu strains.

A spike in the number of hospitals and community clinics, especially in the developing countries in the view of robust investments in healthcare infrastructure, has boosted the sales of flu vaccines through institutional channels. In addition, recognizing the ever-changing trends in retail pharmacy and growing popularity of mail-order pharmacies, market players are focusing on capitalizing on these sales channels.

The Quest for ‘Universal Flu Vaccine’ to Dictate Stakeholders’ Strategies

Growth prospects of flu vaccine market are currently based on affordable cost of flu vaccine and rapid production capabilities along with the stockpiling of flu vaccines for possible pandemics. Considering the unfavorable regulatory scenario in different nations that could lead to shortage of vaccines, market stakeholders are continuously seeking approval for their products in different regions to enable the widespread launch of those products.

flu vaccine north america

As researchers get closer to a universal vaccine for influenza or ‘universal flu vaccine’, a number of players in the market are centered on increasing their investments in R&D activities, boosting manufacturing capabilities and regional product offerings. These aspects played an important role in Sanofi Pasteur’s decision to invest €350 million for establishing a new state-of-the-art vaccine manufacturing facility in Toronto, Canada. Such strategic move is likely to influence other stakeholders to follow suit and up their R&D game. Additionally, as currently available seasonal flu vaccines are limited in addressing all types of flu strains, several startup companies are raising a large amount of funds to develop universal flu vaccines. For example, in July 2019, Osivax, a French biotech company raised €8 million to fast-track development of one vaccine that can prevent all flu infections now and in future.

Decoding the Flu Vaccine Market Structure

The flu vaccine market shows a high level of consolidation, with leading players such as Sanofi Pasteur Inc., GlaxoSmithKline plc., and Seqirus (CSL Limited) collectively accounting for approximately 85-90% revenue share in the market.

With strong geographical presence and large manufacturing facilities, key stakeholders in the flu vaccine market are actively engaged in conducting awareness campaigns, donating funds and free doses of flu vaccines to help fight the onset of influenza, especially in low and mid-income countries, as a part of their Corporate Social Responsibility (CSR) activities. Additionally, M&A activities remain an important strategy for these players to leverage new opportunities and improve financial performance.

Considering strong R&D initiatives and product diversity of key stakeholders, a number of small players are showing a distinct duality in their approach – in addition to extending collaboration with organizations such as WHO, GAVI, and PAHO to offer flu vaccines at affordable rate in developing countries, small players are paying attention to capturing both local and regional markets. Flu vaccine market players such as Hualan Biological Engineering Inc., CNBG shanghai institute, Sinovac Biotech Ltd., and Panacea Biotec Limited are highly likely to follow these strategies during the course of the forecast period, 2019-2029.

flu vaccine market segmentation

The Analyst Speaks

Report authors maintain an optimistic outlook of the flu vaccine market, which is estimated to register a CAGR of approximately 7% during the forecast period. Taking the limitations of existing vaccines into consideration, manufacturers will need to develop more effective vaccines and take new technological approaches for enhancing vaccine production. Advances are further anticipated in universal flu vaccine that will substantially reduce vaccine-production time, provide improved protection, and revolutionize the influenza vaccinology, according to the analysts.

Read More

Flu Vaccine Market: The Triumvirate

The flu vaccine market is influenced by three key global manufacturers. Pharmaceutical & biopharmaceutical companies Sanofi S.A., GlaxoSmithKline plc., and CSL Limited have a stronghold on the flu vaccines market, holding approximately 85% to 90% share. Manufacturers of flu vaccines are mainly competing on the basis of their geographical product footprint, collaborations, superior efficacy of the product, etc. These three manufacturers are mostly engaging in mergers, acquisitions, and partnerships to enhance their revenue generation across all regions. For example, in August 2015, CSL limited acquired Novartis’s flu vaccine business. Similarly, in August 2017, Sanofi S.A. acquired 100% of the company Protein Sciences, which used to manufacture flu vaccine.

Flu Vaccination Rate Highest in European Countries

Flu vaccination is rapidly increasing in various regions, which can be attributed to extended efforts from governments to increase awareness about flu, as well as initiatives undertaken by organizations such as World Health Organization (WHO), Global Alliance for Vaccines and Immunization (GAVI), The Pan American Health Organization (PAHO), etc. The enhanced focus of various governments across the world on controlling the spread of infectious diseases can be largely attributed to the incidences of various pandemics in the past few decades. These are forcing developing as well as developed countries to take preventive measures to limit outbreaks, especially that of flu pandemic. Flu vaccine acts as an effective preventive measure for the prevention of probable spread of influenza. Vaccination rate of flu vaccine is highest in European countries, followed by North America, whereas regions such as Asia Pacific, Latin America, and Middle East & Africa still lag in terms of flu vaccination.

Product Approvals and Subsequent Launches

Flu vaccine manufacturers are seeking approval for their products in different regions to be able to launch their products, which will help them enhance their product footprint as well as revenue generation. Products that have not been approved in any of the regions, such as North America or Europe, are being evaluated for launch in semi-regulated flu vaccine markets such as India, China, and Brazil, which hold a higher potential for revenue generation. For example, afluria quadrivalent of AstraZeneca achieved an expanded age indication for use in people aged 5 years and above in the U.S. for the NH 2017/18 season, and similar approvals were achieved for afluria tetra flu vaccine and afluria quad flu vaccine in Canada and Australia. In February 2017, Zydus Cadila launched tetravalent inactivated influenza vaccine Vaxiflu 4, a seasonal flu vaccine, in India.

Collaborations and Increasing Investments to Enhance Product Offering

Various regional flu vaccine manufacturers are looking for collaborations with larger flu vaccine market players and vice versa to enhance their product offering in different countries. Pfizer has teamed up with German biotech company BioNTech to develop a new generation of flu vaccine that can be made in lesser time and with a lesser amount of capital as compared to the products that are currently available in the flu vaccine market. Many biopharmaceutical companies in the flu vaccine market are looking to increase their investments for boosting the manufacturing of flu vaccine, R&D, and regional product offerings. Sanofi S.A. invested more than US$ 400 million for the construction of a new state-of-the-art vaccine manufacturing facility at Toronto, Ontario, the Canadian headquarters of Sanofi. Manufacturers are continuously looking to improve their production capacity and focus on innovation.

Flu Vaccine Market: Competitive Landscape

This part of the report consists of the profiles of key players in the flu vaccine market based on their market shares, product offerings, differential strategies, marketing approach, and company dashboard. Some of the important players featured in the flu vaccine market report include

  • Sanofi S.A.
  • CSL Limited
  • GlaxoSmithKline plc.
  • AstraZeneca Plc
  • Abbott
  • Serum Institute of India Pvt. Ltd.

Flu Vaccine: Definition

Flu vaccines are biologic products. When vaccinated, these cause the production of antibodies, which prevent infection from the influenza virus. The production of antibodies in the person’s body starts within two weeks of vaccination.

Flu Vaccine Market: About the Report

The company conducted a research study on the flu vaccine market for the forecast period 2019-2029. The report offers a comprehensive evaluation of the business opportunities available in the flu vaccine market, with insights on the current trends, reimbursements, as well as regulatory scenario in the flu vaccine market.

Flu Vaccine Market: Segmentation

The report offers a comprehensive taxonomy of the market based on the product type, dosage form, distribution channel, and region. By product type, the flu vaccine market is segmented into trivalent flu vaccine and quadrivalent flu vaccine. By dosage form, the flu vaccine market is segmented as intramuscular injection, nasal spray, and intradermal shot. By distribution channel, the flu vaccine market is segmented into institutional sales and retail sales. The flu vaccine market has been analyzed across the regions of North America, Latin America, Europe, East Asia, South Asia, Oceania, and Middle East & Africa (MEA).

Additional Questions Answered

Some of the additional questions addressed in this report on the flu vaccine market:

  • What is the overall revenue generation potential of the flu vaccine market across all regions?
  • Who are the key regional and global competitors? What are their portfolios in the flu vaccine market?
  • What is the vaccination rate in various regions?
  • What are the major challenges influencing the growth of the flu vaccine market?

Research Methodology

The market has been estimated based on a supply-demand approach. The market was first calculated based on the vaccination rate in different regions/countries. Some of the other qualitative factors analyzed include the awareness level and the availability of flu vaccine. This information is further validated with rigorous primary research (which includes interviews, surveys, in-person interactions, and the viewpoints of seasoned analysts) and secondary research (which includes verified paid sources, authentic trade journals, and resourceful databases). The research study on the flu vaccine market also includes the top trends and the macro- as well as micro-economic factors shaping the flu vaccine market. With this approach, the report on the flu vaccine market estimates the industry attractiveness of every major segment in the market over the forecast period.

Company Profiles:

  • Sanofi Pasteur Inc. (Sanofi S/A)
  • AstraZeneca
  • CSL Ltd. (Seqirus)
  • Abbott 
  • GlaxoSmithKline Plc.
  • Serum Institute of India Pvt. Ltd.

 

Back To Top